Summary
Global Markets Direct’s, ‘Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2016’, provides an overview of the Opioid-Induced Constipation (OIC) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opioid-Induced Constipation (OIC) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC)
- The report reviews pipeline therapeutics for Opioid-Induced Constipation (OIC) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Opioid-Induced Constipation (OIC) therapeutics and enlists all their major and minor projects
- The report assesses Opioid-Induced Constipation (OIC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Opioid-Induced Constipation (OIC)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Opioid-Induced Constipation (OIC)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Develco Pharma Schweiz AG
Ironwood Pharmaceuticals, Inc.
Shionogi & Co., Ltd.
Sucampo Pharmaceuticals, Inc.
Synergy Pharmaceuticals, Inc.
Theravance Biopharma, Inc.
Valeant Pharmaceuticals International, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Opioid-Induced Constipation (OIC) Overview 7
Therapeutics Development 8
Pipeline Products for Opioid-Induced Constipation (OIC) - Overview 8
Pipeline Products for Opioid-Induced Constipation (OIC) - Comparative Analysis 9
Opioid-Induced Constipation (OIC) - Therapeutics under Development by Companies 10
Opioid-Induced Constipation (OIC) - Therapeutics under Investigation by Universities/Institutes 11
Opioid-Induced Constipation (OIC) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Opioid-Induced Constipation (OIC) - Products under Development by Companies 15
Opioid-Induced Constipation (OIC) - Products under Investigation by Universities/Institutes 16
Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development 17
Develco Pharma Schweiz AG 17
Ironwood Pharmaceuticals, Inc. 18
Shionogi & Co., Ltd. 19
Sucampo Pharmaceuticals, Inc. 20
Synergy Pharmaceuticals, Inc. 21
Theravance Biopharma, Inc. 22
Valeant Pharmaceuticals International, Inc. 23
Opioid-Induced Constipation (OIC) - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
(axelopran sulfate + oxycodone hydrochloride) - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
axelopran sulfate - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
dolcanatide - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
linaclotide - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
lubiprostone - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
methylnaltrexone bromide - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
methylnaltrexone bromide - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
naldemedine tosylate - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
naloxone hydrochloride PR - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Opioid-Induced Constipation (OIC) - Dormant Projects 64
Opioid-Induced Constipation (OIC) - Discontinued Products 65
Opioid-Induced Constipation (OIC) - Product Development Milestones 66
Featured News & Press Releases 66
Jun 06, 2016: Shionogi Announces Acceptance Of New Drug Application In The U.S. For Naldemedine For The Treatment Of Opioid-Induced Constipation 66
May 23, 2016: Two Naldemedine Phase III Studies Show Consistent Improvement Of Opioid-Induced Constipation 66
Apr 04, 2016: Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR 67
Mar 30, 2016: Shionogi Submits New Drug Applications In Japan And The U.S. For Naldemedine For The Treatment Of Opioid-Induced Constipation 67
Feb 19, 2016: Naldemedine Phase 3 Study Shows Significant Improvement for Patients with Opioid-Induced Constipation 67
Nov 30, 2015: Ironwood Reports Positive Top-Line Data from Phase II Trial of Linaclotide in Adult Patients With Opioid-Induced Constipation 68
Sep 10, 2015: Theravance Biopharma Presents Positive Clinical Data on Fixed-Dose Combination (FDC) of Axelopran (TD-1211) and Oxycodone at PAINWeek 2015 69
Sep 08, 2015: Valeant And Progenics Announce FDA Acceptance Of NDA Submission For Oral RELISTOR 70
Aug 03, 2015: Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 70
Jun 24, 2015: Shionogi Announces That Naldemedine Met The Primary Endpoint In Its First Japanese Phase 3 Study For The Treatment Of Opioid - Induced Constipation In Cancer Patients 71
Jun 03, 2015: RELISTOR Receives European Approval for Expanded Indication to Treat All Opioid-Induced Constipation 71
May 19, 2015: Phase IIb Data Show Once-Daily Naldemedine Provides Significant Improvement For Patients With Opioid-Induced Constipation 71
May 15, 2015: Sucampo Announces Clinical Data on Lubiprostone to be Presented at Digestive Disease Week 72
Apr 24, 2015: RELISTOR Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain 72
Mar 30, 2015: Shionogi Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 74
Disclaimer 75
List of Tables
Number of Products under Development for Opioid-Induced Constipation (OIC), H2 2016 8
Number of Products under Development for Opioid-Induced Constipation (OIC) - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Opioid-Induced Constipation (OIC) - Pipeline by Develco Pharma Schweiz AG, H2 2016 17
Opioid-Induced Constipation (OIC) - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016 18
Opioid-Induced Constipation (OIC) - Pipeline by Shionogi & Co., Ltd., H2 2016 19
Opioid-Induced Constipation (OIC) - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 20
Opioid-Induced Constipation (OIC) - Pipeline by Synergy Pharmaceuticals, Inc., H2 2016 21
Opioid-Induced Constipation (OIC) - Pipeline by Theravance Biopharma, Inc., H2 2016 22
Opioid-Induced Constipation (OIC) - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 23
Assessment by Monotherapy Products, H2 2016 24
Assessment by Combination Products, H2 2016 25
Number of Products by Stage and Target, H2 2016 27
Number of Products by Stage and Mechanism of Action, H2 2016 29
Number of Products by Stage and Route of Administration, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 33
Opioid-Induced Constipation (OIC) - Dormant Projects, H2 2016 64
Opioid-Induced Constipation (OIC) - Discontinued Products, H2 2016 65
List of Figures
Number of Products under Development for Opioid-Induced Constipation (OIC), H2 2016 8
Number of Products under Development for Opioid-Induced Constipation (OIC) - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 12
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Targets, H2 2016 26
Number of Products by Stage and Targets, H2 2016 26
Number of Products by Mechanism of Actions, H2 2016 28
Number of Products by Stage and Mechanism of Actions, H2 2016 28
Number of Products by Routes of Administration, H2 2016 30
Number of Products by Stage and Routes of Administration, H2 2016 30
Number of Products by Molecule Types, H2 2016 32
Number of Products by Stage and Molecule Types, H2 2016 32
